Best Stocks Under $20.00 for 2018

The stock market has had an incredible bull-run since the Great Recession of 2008 and 2009. Stocks continue to hit new all-time highs and the price-to-earnings ratios of most S&P 500 companies look very expensive. Many investors are having trouble finding low-priced stocks that haven't already appreciated greatly during the last decade. It's hard to find a good deal on Wall Street right now when even small S&P 500 companies are trading at market caps above $1 billion.

Stocks have gotten expensive both in-terms of share price and their valuation relative to earnings. In more normal markets, a typical S&P 500 company has traded at about fifteen times their earnings. Most stocks are currently trading closer to 25 times their annual earnings. While the stock market has become more expensive as a whole, there are still a handful of undervalued stocks that are trading at less than $20.00 per share.

Value investing opportunities do exist if you're looking in the right places. Putting together a list of the best stocks under $20.00 requires investors to look at smaller and riskier companies and in sectors that are either undiscovered or unloved by the market as a whole. Some of these cheap stocks may not look especially attractive today, but long-term investors will profit if they are willing to exercise patience and hold on to shares of these comapnies through multiple economic cycles.

Some of these companies are solid investing ideas because they are too little and considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unloved and untested areas of the market. You may find even find crypto stocks, marijuana stocks and bitcoin stocks on this list. Others have been beat up by Mr. Market after a long period of slowing profits, but are now actively trying to turn around their business and bounce back. These low-priced stocks operate in a lot of different industries, but these picks all carry two common characteristics. They all have a super-low share price of $20.00 or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

#1 - Ra Pharmaceuticals (NASDAQ:RARX)

Stock Price: $16.42
Market Cap: $531.03 million
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $20.75 (26.4% Upside)

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

#2 - Ichor (NASDAQ:ICHR)

Stock Price: $17.66
Market Cap: $455.02 million
P/E Ratio: 7.3
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $38.60 (118.6% Upside)

Ichor Holdings Ltd. engages in the design, engineering, and manufacturing of fluid delivery subsystems for semiconductor capital equipment. It offers gas and chemical delivery systems and manufactures components for internal use in fluid delivery systems and for direct sales of the customers. The gas delivery subsystems deliver, monitor, and control precise quantities of the specialized gases used in semiconductor manufacturing processes such as etch and deposition. The chemical delivery subsystems blend and dispense the reactive liquid chemistries used in semiconductor manufacturing processes such as chemical-mechanical planarization, electroplating, and cleaning. The company was founded on January 30, 2012 and is headquartered in Fremont, CA.

#3 - Mesa Air Group (NASDAQ:MESA)

Stock Price: $13.60
Market Cap: $328.11 million
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $17.80 (30.9% Upside)

Mesa Air Group, Inc. operates as the holding company for Mesa Airlines, Inc., which provides regional air services under capacity purchase agreements with the American Airlines and the United Airlines. As of March 31, 2018, it operated 145 aircraft with approximately 610 daily departures to 110 cities in the United States, Canada, Mexico, the Bahamas, and Cuba. Mesa Air Group, Inc. was founded in 1982 and is headquartered in Phoenix, Arizona.

#4 - Construction Partners (NASDAQ:ROAD)

Stock Price: $10.29
Market Cap: $562.84 million
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $15.10 (46.7% Upside)

Construction Partners, Inc., an infrastructure and road construction company, provides construction products and services to public and private sectors. Its services cover construction of highways, roads, bridges, airports, and commercial and residential sites. The company provides site development, paving, utility and drainage systems, as well as supplies hot mix asphalt. It serves customers primarily in Alabama, Florida, Georgia, North Carolina, and South Carolina. The company was formerly known as SunTx CPI Growth Company, Inc. and changed its name to Construction Partners, Inc. in September 2017. Construction Partners, Inc. was founded in 2001 and is headquartered in Dothan, Alabama.

#5 - Ladder Capital (NYSE:LADR)

Stock Price: $17.48
Market Cap: $1.96 billion
P/E Ratio: 10.3
Dividend Yield: 7.38 %
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $17.2857 (-1.1% Upside)

Ladder Capital Corp operates as a real estate investment trust in the United States. The company operates through three segments: Loans, Securities, and Real Estate. The Loans segment originates conduit first mortgage loans that are secured by cash-flowing commercial real estate; and originates and invests in balance sheet first mortgage loans secured by commercial real estate properties that are undergoing transition, including lease-up, sell-out, and renovation or repositioning. It also invests in note purchase financings, subordinated debt, mezzanine debt, and other structured finance products related to commercial real estate. The Securities segment invests in commercial mortgage-backed securities and the U.S. Agency Securities. The Real Estate segment owns and invests in a portfolio of commercial and residential real estate properties, such as leased properties, office buildings, a warehouse, and condominium units. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. Ladder Capital Corp was founded in 2008 and is headquartered in New York, New York.

#6 - Scorpio Tankers (NYSE:STNG)

Stock Price: $1.75
Market Cap: $666.58 million
P/E Ratio: -3.8
Dividend Yield: 2.17 %
Consensus Rating: Buy
Ratings Breakdown: 9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $4.0250 (130.0% Upside)

Scorpio Tankers Inc., together with its subsidiaries, engages in the seaborne transportation of refined petroleum products worldwide. As of March 22, 2018, its fleet consisted of 109 tankers, including 38 LR2, 12 LR1, 45 MR, and 14 Handymax tankers with an average age of approximately 2.6 years; and 20 time or bareboat chartered-in tankers, which include 2 LR2, 10 MR, and 8 Handymax tankers. The company was founded in 2009 and is based in Monaco.

#7 - Clearside Biomedical (NASDAQ:CLSD)

Stock Price: $5.33
Market Cap: $174.21 million
Consensus Rating: Buy
Ratings Breakdown: 7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $22.40 (320.3% Upside)

Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema. The company also engages in the development of therapies in various areas, such as gene therapy for inherited retinal disorders, neovascular age-related macular degeneration, and other ocular diseases. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.

#8 - G4S/ADR (OTCMKTS:GFSZY)

Stock Price: $14.35
Market Cap: $4.56 billion
Dividend Yield: 2.74 %
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: N/A

G4S plc, together with its subsidiaries, engages in the provision of security and related services in the United Kingdom, Ireland, Africa, the Asia Pacific, the Middle East, India, Latin America, Europe, and North America. The company offers integrated solutions, including analytics and intelligence, technology and software, consulting and risk management, monitoring and response, and manned and mobile security, as well as systems design, built, and integration services. It also provides electronic monitoring, secure health, forensic medical and police support, secure support, and custody, detention, and rehabilitation services. In addition, the company offers cash solutions, such as cash management software and systems, cash recycling, international secure logistics, ATM replenishment and engineering, cash processing, and cash in transit services. It serves government, financial institutions, private energy and utilities, and ports and airports, as well as transportation and logistics, leisure and tourism, corporate and industrial, and retail sectors. G4S plc was founded in 1901 and is based in London, the United Kingdom.

#9 - Kura Oncology (NASDAQ:KURA)

Stock Price: $15.55
Market Cap: $603.81 million
P/E Ratio: -10.2
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $28.00 (80.1% Upside)

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have mutations in, or other dysregulation of, the mitogen-activated protein kinase; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia. The company was founded in 2014 and is headquartered in San Diego, California.

#10 - Akoustis Technologies (NASDAQ:AKTS)

Stock Price: $5.01
Market Cap: $128.63 million
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $12.0833 (141.2% Upside)

Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., develops, designs, manufactures, and sells radio frequency (RF) filter products for the mobile wireless device industries in the United States. The company operates through two segments, Foundry Fabrication Services and RF Filters. The Foundry Fabrication Services segment provides engineering review services; and smart systems technology and commercialization center foundry, as well as manufacturing and microelectromechanical systems foundry services. The RF Filters segment consists of amplifier and filter products. It offers RF filters for mobile wireless devices, such as smartphones and tablets, cellular infrastructure equipment, and Wi-Fi premise equipment. Akoustis Technologies, Inc. is headquartered in Huntersville, North Carolina.

#11 - Nomad Foods (NYSE:NOMD)

Stock Price: $19.96
Market Cap: $3.55 billion
P/E Ratio: 15.2
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $22.00 (10.2% Upside)

Nomad Foods Limited manufactures and distributes frozen foods in Western Europe. The company offers fish products, including fish fingers, coated fish, and natural fish; vegetables, such as peas and spinach; and poultry and meat products comprising nuggets, grills, and burgers. It also provides meals products that include ready to cook noodles, pasta, lasagne, pancakes, and other ready-made meals; and other products, such as soups, pizzas, and bakery goods. The company sells its products to supermarkets and food retail chains directly or through distribution arrangements primarily under the Birdseye, Findus, and Iglo brands. Nomad Foods Limited is based in Feltham, the United Kingdom.

#12 - Viewray (NASDAQ:VRAY)

Stock Price: $9.42
Market Cap: $703.93 million
P/E Ratio: -9.2
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $12.5833 (33.6% Upside)

ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company's software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.

#13 - Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Stock Price: $13.99
Market Cap: $189.73 million
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $29.25 (109.1% Upside)

Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using small molecule nucleic acid hybrid (SMNH) chemistry platform. The company's lead SMNH product candidate is inarigivir soproxil, for the treatment of chronic hepatitis B virus (HBV). It is also developing SMNH product candidates, including STimulator of INterferon Genes agonist, an immunotherapeutic agent for the potential treatment of selected cancers. Spring Bank Pharmaceuticals, Inc. has strategic collaborations with Gilead Sciences, Inc. to conduct a Phase II trial examining the co-administration of inarigivir and tenofovir alafenamide in patients infected with HBV. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.

#14 - Quantenna Communications (NASDAQ:QTNA)

Stock Price: $17.20
Market Cap: $636.62 million
P/E Ratio: 123.2
Consensus Rating: Buy
Ratings Breakdown: 9 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $20.00 (16.3% Upside)

Quantenna Communications, Inc. designs, develops, and markets wireless communication solutions enabling wireless local area networking in the United States and internationally. The company's solutions portfolio comprises radio frequency chips and digital baseband chips, which support the IEEE Wi-Fi standards, including 802.11n, 802.11ac, and draft 802.11ax. It offers its products for home networking applications, including home gateways, repeaters, and set-top boxes, as well as retail, outdoor, small and medium business, enterprise, and consumer electronics applications. The company sells its Wi-Fi solutions directly to original equipment manufacturers and original design manufacturers; and third-party distributors. Quantenna Communications, Inc. was founded in 2005 and is headquartered in Fremont, California.

#15 - Earthstone Energy (NYSE:ESTE)

Stock Price: $9.43
Market Cap: $600.11 million
P/E Ratio: 14.0
Consensus Rating: Buy
Ratings Breakdown: 9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $13.8750 (47.1% Upside)

Earthstone Energy, Inc., an oil and natural gas development and production company, operates in the up-stream segment of the oil and natural gas industry in the United States. Its asset portfolio includes the Midland Basin of west Texas and the Eagle Ford trend of south Texas. As of December 31, 2017, the company operated 91 gross Eagle Ford wells; and 12 gross Austin Chalk wells, as well as had 79,976 thousand barrels of oil equivalent (MBOE) of total proved reserves, 19,961 MBOE of proved developed reserves, and 60,015 MBOE of proved undeveloped reserves. Earthstone Energy, Inc. was founded in 1969 and is headquartered in The Woodlands, Texas.

#16 - Rosehill Resources (NASDAQ:ROSE)

Stock Price: $5.65
Market Cap: $205.37 million
P/E Ratio: 2.5
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $12.30 (117.7% Upside)

Rosehill Resources Inc., an independent oil and natural gas company, focuses on the acquisition, exploration, development, and production of unconventional oil and associated liquids-rich natural gas reserves in the Permian Basin. As of December 31, 2017, its portfolio included 39 gross operated producing horizontal wells and 3 gross operated horizontal wells in the Northern Delaware Basin; and working interests in approximately 14,762 gross acres in the Northern and Southern Delaware Basin with an inventory of 530 gross operated and non-operated potential horizontal drilling locations. The company was founded in 2015 and is headquartered in Houston, Texas.

#17 - Repsol (OTCMKTS:REPYY)

Stock Price: $18.50
Market Cap: $28.68 billion
P/E Ratio: 9.9
Dividend Yield: 4.91 %
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: N/A

Repsol, S.A. operates as an integrated energy company worldwide. Its Upstream segment engages in the exploration and development of crude oil and natural gas reserves. The company's Downstream segment in involved in refining and petro chemistry; trading and transportation of crude oil and oil products; commercialization of oil products, petrochemical, and LPG; and the commercialization, transport, and regasification of natural gas and liquefied natural gas (LNG). The company also distributes and markets asphalt products; installs, operates, and manages gas stations; provides maritime services; commercializes platform for customer management and marketing plans; constructs and operates oil refineries; refines and markets hydrocarbons; provides human resource services; distributes and supplies electricity; leases logistics assets; and develops new energy source projects, as well as produces and markets lubricants and biofuels. Further, it is involved in fuel marketing, research activities, regasification of LNG, marketing of chemical products, trading and transport, insurance and reinsurance, and financing activities. The company was formerly known as Repsol YPF, S.A. and changed its name to Repsol, S.A. in May 2012. Repsol, S.A. was founded in 1927 and is headquartered in Madrid, Spain.

#18 - Senseonics (NYSEAMERICAN:SENS)

Stock Price: $3.69
Market Cap: $434.88 million
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $6.00 (62.6% Upside)

Senseonics Holdings, Inc., a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days. The company has a research and development license agreement with TypeZero Technologies, Inc. and Roche Diabetes Care, Inc. to develop a closed loop diabetes management system that allow users to automatically maintain tight glucose control while avoiding hypoglycemia. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

#19 - AquaVenture (NYSE:WAAS)

Stock Price: $18.65
Market Cap: $480.32 million
P/E Ratio: -19.0
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $23.00 (23.3% Upside)

AquaVenture Holdings Limited provides water-as-a-service solutions in North America, the Caribbean, and South America. The company operates in two segments, Seven Seas Water and Quench. It offers desalination and wastewater treatment solutions for governmental, municipal, industrial, and hospitality customers; and point-of-use filtered water systems and related services to approximately 40,000 institutional and commercial customers. The company was founded in 2006 and is headquartered in Road Town, British Virgin Islands.

#20 - Obseva (NASDAQ:OBSV)

Stock Price: $16.83
Market Cap: $637.27 million
P/E Ratio: -7.5
Consensus Rating: Buy
Ratings Breakdown: 7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $29.8571 (77.4% Upside)

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age. The company was founded in 2012 and is headquartered in Plan-les-Ouates, Switzerland.